MSD diabetes drug found to contain possible carcinogen

Health authorities have revealed they continued to allowed the sale of Januvia, which has higher levels of a nitrosamine compound than generally allowed, to avoid a shortage.


The active ingredient in MSD’s diabetes drug Januvia, sitagliptin, has been found to be contaminated with substance that potentially causes cancer.

The contaminant, a nitrosamine compound, was found in some samples of sitagliptin by the US Food and Drug Administration (FDA), Bloomberg News reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs